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Clinical trials have shown that a small proportion of Dukes’ C
stage CRC patients derive a survival benefit from adjuvant
chemotherapy using 5-FU-based regimes (Moertel, 1994).
Predictive factors for the efficacy of this treatment include the
presence of tumour-specific genetic alterations such as TP53
mutation (Ahnen et al, 1998) and the microsatellite instability
(MSI) phenotype (Elsaleh et al, 2000). In addition to somatic alter-
ations, genotype-related differences in the level of expression and
function of various genes involved in the response to 5-FU may
also have an impact upon the efficacy of treatment. Identification
of both the somatic and germ-line factors that influence tumour
cell response to 5-FU would greatly improve the selection of CRC
patients to receive this form of treatment. Good predictive markers
would be particularly useful for Dukes’ B stage CRC where 
the benefits of adjuvant chemotherapy remain controversial
(Anonymous, 1999; Mamounas et al, 1999). 
The TS enzyme catalyses conversion of dUMP to dTMP, the
latter being the sole source of thymidine nucleotides necessary for
DNA synthesis. Inhibition of TS activity is thought to be one of
the major mechanisms for the antitumoural properties of 5-FU
(Santi et al, 1974). The cytotoxic effect of this drug occurs through
the action of the 5-FU metabolite, FdUMP, which competes with
dUMP for a binding site on the TS protein. Numerous in vitro
(Johnston et al, 1992; Beck et al, 1994; van Triest et al, 1999) and
clinical studies (Peters et al, 1994; Lenz et al, 1996; Leichman
et al, 1997; Salonga et al, 2000) have demonstrated a correlation
between TS levels and response to 5-FU, with high levels gener-
ally being associated with a poor response. Identification of the
factors that regulate TS expression would therefore be of consider-
able benefit in understanding the mechanisms of tumour cell resis-
tance to 5-FU. 
Recent studies on the enhancer region of the TS promoter have
identified a 28-bp double or triple tandem repeat polymorphism
(Horie et al, 1995) that has been associated with the level of TS
expression both in vitro (Horie et al, 1995) and in clinical tumour
specimens (Kawakami et al, 1999). Triple repeat homozygotes
(3R/3R) are associated with a 2–4-fold higher TS activity level
compared to double repeat homozygotes (2R/2R) or heterozygotes
(2R/3R). Therefore it might be expected that the TS polymor-
phism, through its influence on TS activity level, could influence
the clinical outcome following treatment with 5-FU. In the present
study we have examined the survival benefit from 5-FU in a large
series of Dukes’ C CRC patients that were stratified according to
TS genotype. 
METHODS 
Tumour specimens 
Tumours analysed in this study were from a larger series of Dukes’
C CRC described recently by our laboratory (Elsaleh et al, 2000).
A total of 221 cases were studied, of which 117 received standard,
6 monthly cycles of 5-FU-based adjuvant chemotherapy. Because
of a bias towards the selection of younger patients to receive
chemotherapy, an upper age limit of 70 years was set for those in
the non-chemotherapy group. Consequently, the median age of
patients in the chemotherapy and non-chemotherapy groups was
almost identical (62 vs 63 years, respectively). There were no
significant differences between the 2 groups for the features of
A polymorphism in the enhancer region of the
thymidylate synthase promoter influences the survival
of colorectal cancer patients treated with 5-fluorouracil 
B Iacopetta1, F Grieu2, D Joseph2,3 and H Elsaleh1,2
1Department of Surgery, University of Western Australia, Nedlands 6907, Australia; 2Department of Radiation Oncology, Sir Charles Gairdner Hospital,
Nedlands 6009, Australia; 3Department of Medicine, University of Western Australia, Nedlands 6907, Australia 
Summary High levels of thymidylate synthase (TS) expression have been associated with poor survival of colorectal cancer (CRC) patients to 5-
fluorouracil (5-FU)-based chemotherapy. Recent evidence suggests that a polymorphism within the enhancer region of the TS gene promoter
can influence TS expression, with the triple repeat homozygote (3R/3R) being associated with significantly higher tumour TS levels than either
the double repeat homozygote (2R/2R) or heterozygotes (2R/3R). In the present study we investigated whether TS genotype was associated
with the degree of survival benefit from chemotherapy in 221 Dukes’ C stage CRC patients. Patients with the 3R/3R polymorphism (n = 58, 26%)
showed no significant long-term survival benefit from chemotherapy (RR = 0.62, 95% CI: 0.30–1.25, P = 0.18), whereas those with the 2R/2R or
2R/3R genotype (n = 163, 74%) showed significant gains in survival from this treatment (RR = 0.52, 95% CI: 0.52–0.82, 
P = 0.005). These results demonstrate that a polymorphism within the TS gene, probably through its effect on TS expression levels, can influence
the survival benefit obtained by CRC patients from 5-FU-based chemotherapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: colorectal cancer; adjuvant chemotherapy; thymidylate synthase; polymorphism 
827
Received 26 October 2000 
Revised 21 June 2001 
Accepted 3 July 2001 
Correspondence to: B Iacopetta 
British Journal of Cancer (2001) 85(6), 827–830
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2007, available online at http://www.idealibrary.com on  http://www.bjcancer.compatient sex, tumour site, histological grade, MSI phenotype or
TP53 mutation (results not shown). Information on adjuvant treat-
ment and patient survival was obtained from hospital records and
the Health Department of Western Australia. The majority of non-
chemotherapy patients were from 1985–1990 whereas all
chemotherapy-treated patients were from 1991–1998. Median
follow-up time was 115 months for non-chemotherapy-treated
patients and 29 months for chemotherapy-treated patients. Only
deaths due to recurrence of CRC were considered in the survival
analysis. For comparison of TS genotype frequencies, DNA from
breast cancer, Dukes’ B CRC, and non-cancer patients from the
same institute were also analysed. 
TS genotyping 
Formalin-fixed, paraffin-embedded surgical tumour specimens
were used as the source of DNA for TS genotyping of each patient
in the study. The TS gene is located on chromosomal arm 18p, a
region showing frequent allelic loss in CRC. Because primary
CRCs always contain a relatively large proportions of non-tumour
tissue (stroma, lymphoid, non-tumour areas) contributing germline
DNA, genotyping of the TS gene is unlikely to have been affected
by the presence of LOH at 18p in the tumour DNA. DNA was
extracted following proteinase-K digestion of 20 µm tissue
sections as previously described by our laboratory (Soong and
Iacopetta, 1997). PCR amplification of the TS promoter enhancer
region containing the double and triple tandem repeats was carried
out using the following primers: 
forward 5’ AAAAGGCGCGCGGAAGGGGTCCT 3’ 
reverse 5’ TCCGAGCCGGCCACAGGCAT 3’ 
PCR reactions were carried out in 15 µl volumes comprising 1 µl
of DNA preparation, 0.2 U of Taq Polymerase (Qiagen, Australia),
primers at a final concentration of 0.4 µM, DMSO at a final
concentration of 10%, Mg2+ at a final concentration of 3 mM and 
5  × reaction mix (Bio Tech International, Perth) containing
nucleotides and buffer. A total of 32 PCR cycles were carried out
(94˚C for 40 s, 62˚C for 40 s and 72˚C for 1 min) following hot-
start at 94˚C for 5 min during which time DNA was added. PCR
product containing triple repeats (144 bp) was distinguished from
that containing double repeats (116 bp) by electrophoretic separa-
tion on 3% agarose gels. Patients who were homozygous for the
triple repeat (3R/3R) displayed only the larger PCR product, those
homozygous for the double repeat (2R/2R) displayed only the
smaller PCR product, while heterozygous individuals (2R/3R)
showed both the larger and smaller PCR products. All TS
genotype results were confirmed at least once by separate PCR
reaction. 
Statistical analysis 
Associations between TS genotype and various clinico-patho-
logical features of tumours were tested by chi-square analysis.
Survival curves were constructed using the method of
Kaplan–Meier and compared using the log-rank test. Cox regres-
sion analysis was used to estimate the effect of chemotherapy on
survival. Statistical significance was assumed when P < 0.05 and
all analyses were carried out using the SPSS statistical software
package. 
RESULTS 
TS genotype frequencies for non-cancer, breast cancer and Dukes’
B and C CRC patients are compared in Table 1 against frequencies
reported by Marsh et al (1999) for a Caucasian population. The
3R/3R homozygote frequency in non-cancer and Dukes’ B CRC
patients is similar to that reported by Marsh et al, however its
frequency in breast carcinoma and Dukes’ C CRC patients is
significantly lower (P < 0.05 and P < 0.04, respectively). Since it
has been reported that TS levels in tumours from individuals with
the 3R/3R genotype are significantly higher than those found in
tumours from either 2R/2R or 2R/3R individuals (Kawakami et al,
1999), the latter 2 groups were combined for the purposes of the
current analysis. No significant associations between TS genotype
and any of the clinicopathological features or genetic alterations
were observed (Table 2). A trend for increased frequency of the
3R/3R genotype in patients with poorly differentiated tumours was
not confirmed by analysis of larger numbers of well and poorly
differentiated tumours (17/60 vs 37/109 respectively, P = NS). 
The survival benefit from chemotherapy in the 2 patient groups
stratified according to TS genotype is shown in Figure 1. A short-term
benefit was apparent for the 3R/3R genotype, but no significant
long-term gains from the use of chemotherapy were seen for this
patient group (P = 0.18). In contrast, the combined 2R/2R and
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Table 2 Association of TS genotype with clinico-pathological features and
genetic alterations in Dukes’ C CRC 
Feature (n) 2R/2R or 2R/3R (%) 3R/3R (%)  P
Total (221) 163 (74) 58 (26) 
Male (117) 88 (75) 29 (25) 
Female (104) 75 (72) 29 (28) 0.60 
Left-sided (128) 93 (73) 35 (27) 
Right-sided (91) 68 (75) 23 (25) 0.73 
< 62 years (110) 81 (74) 29 (26) 
≥ 62 years (111) 82 (74) 29 (26) 0.97 
Well differentiated (22) 18 (82) 4 (18) 
Moderately differentiated (143) 108 (76) 35 (24) 
Poorly differentiated (48) 30 (62) 18 (38)  0.13 
No chemotherapy (104) 78 (75) 26 (25) 
Chemotherapy (117) 85 (73) 32 (27) 0.69 
MSI– (168) 119 (71) 49 (29) 
MSI+ (11) 10 (91) 1 (9) 0.15 
TP53 IHCa normal (131) 101 (77) 30 (23) 
TP53 IHC abnormal (56) 39 (70) 17 (30)  0.28 
TP53 wild-type (137) 104 (76) 33 (24) 
TP53 mutation (64) 44 (69) 20 (31) 0.28 
aIHC: immunohistochemical detection of TP53 overexpression.
Table 1 TS genotype frequency 
Study (n) 2R/2R 2R/3R 3R/3R  P a
Marsh et al (96) 19% 43% 38% 
Present study 
non-cancer (91) 22% 44% 34% NS 
breast cancer (317) 22% 51% 27%  < 0.05 
Dukes’ B CRC (83) 17% 43% 40% NS 
Dukes’ C CRC (221) 28% 46% 26%  < 0.04 
aFrequency of the 3R/3R genotype is compared to that reported by Marsh 
et al (1999). 2R/3R patient group showed significant benefit (Figure 1B). Cox
regression analysis of the survival benefit conferred by
chemotherapy in TS genotype subgroups is shown in Table 3. In
chemotherapy-treated patients, the 3R/3R group showed worse
survival compared to the combined 2R/2R and 2R/3R group (RR =
1.48, 95% CI: 0.78–2.80, P = 0.23). 
DISCUSSION 
In several studies of tumour cell lines (Johnston et al, 1992; Beck et al,
1994; van Triest et al, 1999) and clinical samples (Peters et al,
1994; Lenz et al, 1996; Leichman et al, 1997; Salonga et al, 2000),
the TS activity level was found to be predictive for response to 5-
FU. Most studies report that high tumour TS levels are associated
with poor response to chemotherapy, however Johnston et al
(1994) found no association with patient survival. Additionally,
studies carried out in vitro (Horie et al, 1995) and on gastro-
intestinal tumours (Kawakami et al, 1999) have shown that the
3R/3R TS genotype is associated with significantly higher TS
expression levels compared to the 2R/2R and 2R/3R variants. In
the present study we therefore tested the hypothesis that the 3R/3R
genotype, because of its links with higher TS levels, is associated
with less survival benefit from chemotherapy compared to the
2R/2R and 2R/3R genotypes. We used disease-specific survival as
the endpoint in a series of 221 Dukes’ C CRC patients, 117 (53%)
of whom had been treated post-surgically with 5-FU-based
chemotherapy. Although non-randomized, the adjuvant treated
and non-treated patient groups were well matched for age, sex,
tumour site and histological grade. In line with results from clin-
ical trials (Moertel, 1994), the use of chemotherapy was associated
with a significantly reduced risk of death in the overall patient
group (Table 3). 
The frequency of the 3R/3R genotype found in Dukes’ C CRC
patients was lower than that observed in this study for non-cancer
and Dukes’ B CRC patients, as well as that reported recently for
Caucasian individuals (Table 1). It is not known whether the
apparent differences in TS genotype frequencies between the
normal, CRC and breast cancer series shown in Table 1 are real or
whether they merely reflect sample size differences. By influ-
encing TS expression levels and therefore the availability of
thymidylate, an essential precursor of DNA synthesis, TS geno-
type could conceivably be an important factor for cancer develop-
ment and progression. Further studies in large tumour series will
be required to address this interesting possibility. The results
shown in Table 2 suggest however that TS genotype does not
influence the sex, site or age at which CRC develops, nor the histo-
logical grade. The trend for association of the 3R/3R genotype
with poorly differentiated tumours was not confirmed by analysis
of a larger number of cases. The results of our study also suggest
that TS genotype does not influence the pathway of CRC tumori-
genesis (TP53 mutant or MSI phenotype), however it should be
cautioned that the number of cases examined is small. 
The major finding of our work is that CRC patients with 
the 3R/3R TS genotype derive less survival benefit from
chemotherapy than those with the 2R/2R or 2R/3R genotypes
(Figure 1 and Table 3). Some short-term benefit was apparent for
the 3R/3R patient group and this may be related to the observation
by Kawakami et al (1999) that a sizeable fraction of 3R/3R
gastrointestinal cancer patients have low tumour TS levels. These
patients would be expected to derive benefit from 5-FU-based
chemotherapy and may explain the survival benefit seen for the
3R/3R group in the present study. The results of Kawakami et al
(1999) demonstrate that TS levels are not tightly linked to TS
genotype and other, unidentified factors are likely to play a role in
regulating the expression of this gene. The relatively weak associ-
ation observed between TS genotype and survival benefit from
chemotherapy in CRC indicates that direct biochemical or
immunohistochemical evaluation of TS level will be required if
this predictive marker is to find routine clinical use. Although
there are problems with standardization, TS immunohistochem-
istry has been carried out by many laboratories and it should be
possible to distinguish between high- and low-expressing tumours
in routine laboratories. It remains to be determined how additional
TS alleles containing up to 9 copies of the repeat in some ethnic
groups (Marsh et al, 1999) are likely to influence expression levels
and therefore the survival benefit from therapy. 
A recent study found that advanced CRC patients with low
tumour levels of each of the TS, dihydropyrimidine dehydroge-
nase (DPD) and thymidine phosphorylase (TP) enzymes showed
Thymidylate synthase polymorphism in colorectal cancer 829
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Table 3 Univariate analysis of the effect of chemotherapy on survival of
Dukes’ C CRC patients with different TS genotypes 
TS genotype Relative riska 95% CI  P
Total (221) 0.56 0.38–0.82 0.003 
3R/3R (58) 0.62 0.30–1.25 0.18 
2R/2R or 2R/3R (163) 0.52 0.33–0.82 0.005 
aFor each group, the survival of patients treated with chemotherapy is
compared to that of patients treated with surgery alone. 
n = 163
P = 0.005
n = 58
P = 0.18 
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Figure 1 Kaplan–Meier analysis comparing the survival of adjuvant-treated
(chemo+) and non-treated (chemo–) Dukes’ C CRC patient groups having
(A), the 3R/3R TS genotype, (B), the 2R/2R or 2R/3R TS genotype much greater survival benefit from 5-FU than those with high
expression levels (Salonga et al, 2000). The predictive value of
such markers should now be tested in prospective trials in
conjunction with somatic genetic alterations such as TP53 muta-
tion (Ahnen et al, 1998) and MSI (Elsaleh et al, 2000) which have
also been shown to have strong predictive value. It is tempting to
speculate that the recently described methylator phenotype
(Toyota et al, 1999) may be relevant to the observations made by
Salonga et al (2000). Transcriptional silencing of genes such as TS,
TP and DPD by CpG island methylation may be the primary cause
for their reduced expression in some tumour tissues. Further
prospective studies will be required to uncover both genotype-
related and tumour-specific factors that regulate the expression of
genes involved in tumour cell response to 5-FU. 
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